UBR5 antagonizes DNA damage to enhance the doxorubicin resistance of triple-negative breast cancer by p38 signaling

Background: Triple-negative breast cancer (TNBC) is characterized by aggressive behavior and limited treatment options, with chemotherapy resistance posing a significant clinical challenge. UBR5, an E3 ubiquitin ligase, has been consistently reported to be amplified and overexpressed in breast cancers. Materials and methods: This study analyzed 185 TNBC patients to investigate the association between UBR5 expression levels and clinical outcomes. Experimental approaches included in vitro assays using UBR5 knockout or knockdown TNBC cell models treated with doxorubicin and cisplatin, alongside in vivo xenograft models to assess therapeutic responses. Results: High UBR5 expression correlated significantly with poor 5-year disease-free survival (44.0% vs. 82.0% in low UBR5 group) and reduced pathological complete response rates to anthracycline-based neoadjuvant chemotherapy (8.8% vs. 33.3%). In vitro, UBR5 knockout or knockdown sensitized TNBC cells to doxorubicin and cisplatin, enhancing apoptosis and DNA damage accumulation, as evidenced by elevated γ-H2AX levels and impaired DNA damage repair (DDR) pathways, including ATM/CHK2 signaling and key repair proteins (53BP1, RAD51, BRCA1). Mechanistically, UBR5 loss suppressed p38/NF-κB signaling, further compromising DDR and exacerbating chemosensitivity. In vivo, UBR5-deficient xenografts exhibited enhanced doxorubicin responsiveness, an effect mimicked by p38 inhibition. Conclusions: UBR5 serves as a critical mediator of chemoresistance in TNBC by regulating the DNA damage response through the p38 signaling pathway. Targeting UBR5 or p38 signaling presents a promising therapeutic approach to overcome treatment resistance.

• Publication year

  2025

• Venue

  International Journal of Surgery

• Publication date

  2025-08-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/JS9.0000000000003061PMID 40788036PMCID 12626590
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oncogenic RAS induces a distinctive form of non-canonical autophagy mediated by the P38-ULK1-PI4KB axis

  2025cited by this paper
• Transparency In The reporting of Artificial INtelligence – the TITAN guideline

  2025influential reference
• TEX264 drives selective autophagy of DNA lesions to promote DNA repair and cell survival.

  2024cited by this paper
• E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA

  2024cited by this paper
• A review: targeting UBR5 domains to mediate emerging roles and mechanisms – chance or necessity?

  2024cited by this paper
• OTUD5 promotes end-joining of deprotected telomeres by promoting ATM-dependent phosphorylation of KAP1S824

  2024cited by this paper
• UBR5 mediates colorectal cancer chemoresistance by attenuating ferroptosis via Lys 11 ubiquitin-dependent stabilization of Smad3-SLC7A11 signaling

  2024cited by this paper
• CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer

  2024cited by this paper
• Oncogenic RAS Induces a Distinctive Form of Non-Canonical Autophagy Mediated by the P38-ULK1-PI4KB Axis

  2024cited by this paper
• Revolutionizing DNA repair research and cancer therapy with CRISPR–Cas screens

  2023cited by this paper
• Metabolic regulation of homologous recombination repair by MRE11 lactylation.

  2023cited by this paper
• Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4‐mediated Ferroptosis in Colorectal Cancer

  2023cited by this paper
• A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer

  2023cited by this paper
• Deubiquitinase OTUD6A promotes breast cancer progression by increasing TopBP1 stability and rendering tumor cells resistant to DNA-damaging therapy.

  2022cited by this paper
• Rational combinations of targeted cancer therapies: background, advances and challenges

  2022cited by this paper
• Acetylation of p62 regulates base excision repair through interaction with APE1.

  2022cited by this paper
• UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer

  2022cited by this paper
• Targeting DNA damage response pathways in cancer

  2022cited by this paper
• DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities

  2022cited by this paper
• Targeting replication stress in cancer therapy

  2022cited by this paper
• Recent advances in therapeutic strategies for triple-negative breast cancer

  2022cited by this paper
• Diversity and versatility of p38 kinase signalling in health and disease

  2021cited by this paper
• Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

  2021cited by this paper
• UBR5 over-expression contributes to poor prognosis and tamoxifen resistance of ERa+ breast cancer by stabilizing β-catenin

  2020cited by this paper
• Activated Wnt/β-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer.

  2020cited by this paper
• UBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent Apoptosis

  2020cited by this paper
• Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer

  2020cited by this paper
• Targeting ubiquitin protein ligase E3 component N-recognin 5 in cancer cells induces a CD8+ T cell mediated immune response

  2020cited by this paper
• UBR5 regulates proliferation and radiosensitivity in human laryngeal carcinoma via the p38/MAPK signaling pathway

  2020cited by this paper
• Triple-negative breast cancer molecular subtyping and treatment progress

  2020cited by this paper
• E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBPα

  2020cited by this paper
• Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages

  2020cited by this paper
• PPARγ Interaction with UBR5/ATMIN Promotes DNA Repair to Maintain Endothelial Homeostasis.

  2019influential reference
• UBR5 interacts with the replication fork and protects DNA replication from DNA polymerase η toxicity

  2019cited by this paper
• IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer

  2019influential reference
• RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progression

  2019cited by this paper
• Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.

  2019cited by this paper
• ROS and the DNA damage response in cancer

  2018cited by this paper
• State-of-the-art strategies for targeting the DNA damage response in cancer

  2018cited by this paper
• Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells.

  2018influential reference
• Targeting DNA Damage Response Pathways in Cancer

  2017cited by this paper
• E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer.

  2017cited by this paper
• Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion

  2016cited by this paper
• Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin

  2016cited by this paper
• A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy.

  2014cited by this paper
• Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research †

  2012cited by this paper
• Regulation of DNA end joining, resection, and immunoglobulin class switch recombination by 53BP1.

  2011cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• DNA damage, aging, and cancer.

  2009cited by this paper
• Triple-negative breast cancer.

  2008cited by this paper
• The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro

  2008cited by this paper
• EDD Mediates DNA Damage-induced Activation of CHK2*

  2006cited by this paper

• No citing papers are available for this paper.